CD8A and glioma: Moreover, previous preclinical studies demonstrated that silencing glioma tumor cells-derived Gal-1 significantly decreased the number of brain-infiltrating macrophages, Tregs, and MDSC while increasing CD4+ and CD8+ T cells [19,38].